On September 27, 2019, the board of directors of Arcadia Biosciences, Inc. appointed Matthew Plavan, the company’s chief executive officer, to serve as a Class I director of the company. The appointment fills a vacancy on the Board resulting from Rajendra Ketkar’s retirement on September 1, 2019. Mr. Plavan has served as the Company’s chief executive officer since September 1, 2019 and as the Company’s chief financial officer from September 2016 until September 1, 2019. Mr. Plavan has over 30 years of financial and executive leadership experience in the areas of business operations, fiscal management and strategy, commercial partnering, M&A and integration activities, and public and private equity fundraising. Mr. Plavan served in multiple executive capacities, including CFO, COO, CEO, and board member with Cesca Therapeutics, Inc., a company engaged in research, development and commercialization of autologous cell-based therapeutics, from 2005 until 2015. Prior to that, Mr. Plavan held CFO positions with venture and private equity-backed technology companies, including StrionAir, Inc. from 2002 to 2005, and InPhonic, Inc. (formerly Reason Inc.) from 2000 to 2002. Mr. Plavan also held executive finance positions with McKesson Corporation from 1993 to 2000 and audit and advisory management positions with Ernst & Young from 1987 to 1993.